Systematic analysis of proteogenomic methods to link large-scale omics with clinical phenotypes
Approved Research ID: 99933
Approval date: April 26th 2023
Seer aims to collaborate with the UK Biobank Pharma Proteomics Project (UKB-PPP) towards characterization of SARS-CoV-2, the virus that causes COVID19, biomarkers. We plan to support this effort by measuring proteins in blood plasma. We will tune our measurements and how they are summarized to make it easiest for scientific researchers to study not just COVID19, but general disease mechanisms. Under this project, we will gain access to additional measurements, and we will show how to integrate our data with other common data such as clinical measurement, genomic data, and targeted proteomic measurements. We expect the UKB-PPP phase of the project to last 6-9 months in processing the data and releasing it to the broad UKB research community.
By accessing data from this project, we will continue working with the data for the rest of the initial 3-year term to refine the methodologies. During this time, we plan to publish both our methodological results as well as any biological findings to the scientific community. We expect the health community to gain both a reference guide for large data processing and integration of unbiased proteomics measurements with other synergist measurements as well as greater insights into the mechanisms for COVID19 severity.